Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Interim Analysis of a Pan European Stop Tyrosine Kinase Inhibitor Trial in Chronic Myeloid Leukemia : The EURO-SKI study

Blood (2014) 124 (21): 151.

https://doi.org/10.1182/blood.V124.21.151.151

Published: 2014

Journal Articles

Absolute Quantification of Mutant T315I BCR-ABL Transcripts At 6 Months Identifies Imatinib Resistant CML Patients with a Low Probability to Achieve MMR After 12 Months on Second Line Tyrosine Kinase Therapy

Thoralf Lange, MD, Thomas Ernst, MD, Markus Pfirrmann, PhD, Jacqueline Maier, PhD, Martin C. Müller, MD, Franz Gruber, MD, Dietger Niederwieser, MD, Andreas Hochhaus, MD

Blood (2011) 118 (21): 1679.

https://doi.org/10.1182/blood.V118.21.1679.1679

Published: 2011

Journal Articles

Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

Blood (2011) 118 (12): 3228–3235.

https://doi.org/10.1182/blood-2011-02-336685

Published: 2011

Journal Articles

BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet

Simona Soverini, Andreas Hochhaus, Franck E. Nicolini, Franz Gruber, Thoralf Lange, Giuseppe Saglio, Fabrizio Pane, Martin C. Müller, Thomas Ernst, Gianantonio Rosti, Kimmo Porkka, Michele Baccarani, Nicholas C. P. Cross, Giovanni Martinelli

Blood (2011) 118 (5): 1208–1215.

https://doi.org/10.1182/blood-2010-12-326405

Published: 2011

Journal Articles

A Randomized Phase II Study Comparing Imatinib and the Combination of Imatinib and Pegylated Interferon Alpha-2b in Newly Diagnosed Non-High Risk Chronic Myeloid Leukemia (CML) Patients in Complete Hematological Remission After Imatinib Induction Therapy.

Blood (2009) 114 (22): 3280.

https://doi.org/10.1182/blood.V114.22.3280.3280

Published: 2009

Journal Articles

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome–positive leukemia

Blood (2008) 112 (4): 1005–1012.

https://doi.org/10.1182/blood-2008-02-140665

Published: 2008

Includes: Supplemental data

Journal Articles

The Mutation Spectrum of CML Patients Resistant to Imatinib: More Heterogeneous Than Just BCR-ABL Kinase Domain Point Mutations?.

Tuija Lundan, MSc, Franz Gruber, MD, Aleksandra Silye, Henrik Hjorth-Hansen, MD, Ph.D, Ingvild Mikkola, MD, Ph.D, Kari Remes, MD, Ph.D, Bengt Simonsson, MD, Ph.D, Tobias Gedde-Dahl, MD, Ph.D, Kimmo Porkka, MD, Ph.D

Blood (2007) 110 (11): 1948.

https://doi.org/10.1182/blood.V110.11.1948.1948

Published: 2007

Journal Articles

BCR-ABL Kinase Domain Mutations and Their Kinetics on Second Line Dasatinib or Nilotinib Therapy in CML Patients after Imatinib Failure: A Cooperative Evaluation of Four Different Detection Methods.

Thomas Ernst, MD, Franz Gruber, MD, Oliver Pelz-Ackermann, PhD, Martin C. Mueller, MD, Ingvild Mikkola, PhD, Kimmo Porkka, MD, PhD, Dietger Niederwieser, MD, Andreas Hochhaus, MD, Thoralf Lange, MD

Blood (2007) 110 (11): 321.

https://doi.org/10.1182/blood.V110.11.321.321

Published: 2007

Journal Articles

Quantitative Analyses of BCR-ABL Mutations Associated with Imatinib Treatment in CML.

Franz Gruber, MD, Henrik Hjort Hansen, MD, Marita Olsen, Lab.tech., Lene Eggen, Lab.tech., Bjørn Skogen, MD, Tobias Gedde-Dahl, MD, Tuija Lundan, MD, Kimmo Porkka, MD, Bengt Simonsson, MD, Berit Markevärn, MD, Hans Wadenvik, MD, Leif Stenke, MD

Blood (2005) 106 (11): 2000.

https://doi.org/10.1182/blood.V106.11.2000.2000

Published: 2005

Journal Articles

Acquired Extramedullary Resistance to Dasatinib Due to Selection of Philadelphia-Positive Lymphoblast Clone Harboring a T315I BCR-ABL Gene Mutation: Reversal by Dose Escalation and Hydroxyurea.

Tuija Lundan, MSc, Franz Gruber, MD, Martin Hoglund, M.D,PhD, Bengt Simonsson, M.D,PhD, Sakari Knuutila, PhD, Kimmo Porkka, M.D,PhD

Blood (2005) 106 (11): 4579.

https://doi.org/10.1182/blood.V106.11.4579.4579

Published: 2005

NARROW

Interim Analysis of a Pan European Stop Tyrosine Kinase Inhibitor Trial in Chronic Myeloid Leukemia : The EURO-SKI study

Absolute Quantification of Mutant T315I BCR-ABL Transcripts At 6 Months Identifies Imatinib Resistant CML Patients with a Low Probability to Achieve MMR After 12 Months on Second Line Tyrosine Kinase Therapy

Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet

A Randomized Phase II Study Comparing Imatinib and the Combination of Imatinib and Pegylated Interferon Alpha-2b in Newly Diagnosed Non-High Risk Chronic Myeloid Leukemia (CML) Patients in Complete Hematological Remission After Imatinib Induction Therapy.

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome–positive leukemia

The Mutation Spectrum of CML Patients Resistant to Imatinib: More Heterogeneous Than Just BCR-ABL Kinase Domain Point Mutations?.

BCR-ABL Kinase Domain Mutations and Their Kinetics on Second Line Dasatinib or Nilotinib Therapy in CML Patients after Imatinib Failure: A Cooperative Evaluation of Four Different Detection Methods.

Quantitative Analyses of BCR-ABL Mutations Associated with Imatinib Treatment in CML.

Acquired Extramedullary Resistance to Dasatinib Due to Selection of Philadelphia-Positive Lymphoblast Clone Harboring a T315I BCR-ABL Gene Mutation: Reversal by Dose Escalation and Hydroxyurea.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only